NCT06096779 2026-03-06
Kirros
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
15 trialsNCT05953337 2026-03-04
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical
Phase NA Active not recruiting
NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT07377487 2026-02-20
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT06600321 2026-02-17
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1 Recruiting
NCT07191548 2025-10-10
LIVERMET-IRE
Angiodynamics, Inc.
Phase NA Not yet recruiting
NCT05233098 2025-03-06
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
Boston Scientific Corporation
Completed
NCT04926376 2024-11-29
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
ABK Biomedical
Phase NA Completed
NCT02301104 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT05053412 2024-08-02
HEPATIC
Helio Genomics
Completed
NCT02508467 2024-04-12
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
Blueprint Medicines Corporation
Phase 1 Completed
NCT00627042 2014-10-08
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT00969410 2012-04-12
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
AVEO Pharmaceuticals, Inc.
Phase 1 Completed